A novel GPR40 agonist, CNX-011-67, suppresses glucagon secretion in pancreatic islets under chronic glucolipotoxic conditions in vitro

Elevated glucose concentrations lead to increased insulin secretion and suppression of glucagon secretion. In fact, insulin is a physiological inhibitor of glucagon secretion. Type 2 diabetes mellitus (T2DM) patients have defects in insulin secretion. In addition to this, lack of suppression of gluc...

Full description

Saved in:
Bibliographic Details
Published in:BMC research notes 2014-09, Vol.7 (1), p.595, Article 595
Main Authors: Verma, Mahesh Kumar, Biswas, Sanghamitra, Chandravanshi, Bhawna, Neelima, Korrapati, Oommen, Anup M, Jagannath, Madanahalli R, Somesh, Baggavalli P
Format: Article
Language:English
Subjects:
Analysis
Animals
Genes
Glucagon
Glucagon - antagonists & inhibitors
Glucagon - secretion
Glucose
Glucose - toxicity
In Vitro Techniques
Insulin
Islets of Langerhans - drug effects
Islets of Langerhans - secretion
Lipids - toxicity
Pancreas
Pharmaceutical Preparations - administration & dosage
Physiological aspects
Rats
Rodents
Short Report
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Elevated glucose concentrations lead to increased insulin secretion and suppression of glucagon secretion. In fact, insulin is a physiological inhibitor of glucagon secretion. Type 2 diabetes mellitus (T2DM) patients have defects in insulin secretion. In addition to this, lack of suppression of glucagon secretion under elevated glucose concentrations is also observed in T2DM patients. We have earlier shown that GPR40 activation by CNX-011-67 stimulates glucose stimulated insulin secretion (GSIS). Here we extended our studies to examine the impact of GPR40 activation by CNX-011-67 on glucagon secretion from intact islets under both normal and glucolipotoxic conditions. Glucagon secretion from intact rat islets was suppressed under elevated glucose concentration. Activation of GPR40 by CNX-011-67 further suppressed glucagon secretion. Culturing islets under chronic glucolipotoxic (GL) conditions, we have observed increased high glucose mediated glucagon secretion and content which were reduced with GPR40 activation by CNX-011-67. Interestingly, expression of pre-proglucagon gene (GCG) remained unchanged under glucolipotoxicity in the presence or absence of GPR40 activation. Activation of GPR40 by CNX-011-67 can reduce glucagon secretion from pancreatic islets.
ISSN:1756-0500
1756-0500
DOI:10.1186/1756-0500-7-595